Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01379469 · ClinicalTrials.gov registry record · Phase 2
Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01379469: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT01379469 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01379469, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
Primary Outcome
The effect of Carbamazepine on hepatic ATZ load will be measured by the number of hepatocytes with PAS+/diastase-resistant globules and/or steady state levels of ATZ by immunoblot analysis.
Interventions
- DRUG Drug-Carbamazepine (Tegretol XR)
- DRUG Carbamazepine (Tegretol XR) Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Why NCT01379469 stopped before completion
NCT01379469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Drug-Carbamazepine (Tegretol XR) is the first listed.
NCT01379469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01379469 about?
NCT01379469 is a clinical study titled "Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency". The primary objective is to determine if the medication Carbamazepine, can be used as a therapy for patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency .
What is the current status of trial NCT01379469?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-01. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01379469?
The interventions under investigation include: Drug-Carbamazepine (Tegretol XR) (DRUG), Carbamazepine (Tegretol XR) Placebo (DRUG).
Who is sponsoring clinical trial NCT01379469?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01379469's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia